328 related articles for article (PubMed ID: 31252170)
1. A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Momattin H; Al-Ali AY; Al-Tawfiq JA
Travel Med Infect Dis; 2019; 30():9-18. PubMed ID: 31252170
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial.
Arabi YM; Alothman A; Balkhy HH; Al-Dawood A; AlJohani S; Al Harbi S; Kojan S; Al Jeraisy M; Deeb AM; Assiri AM; Al-Hameed F; AlSaedi A; Mandourah Y; Almekhlafi GA; Sherbeeni NM; Elzein FE; Memon J; Taha Y; Almotairi A; Maghrabi KA; Qushmaq I; Al Bshabshe A; Kharaba A; Shalhoub S; Jose J; Fowler RA; Hayden FG; Hussein MA;
Trials; 2018 Jan; 19(1):81. PubMed ID: 29382391
[TBL] [Abstract][Full Text] [Related]
3. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
4. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
Vargas M; Servillo G; Einav S
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
[TBL] [Abstract][Full Text] [Related]
5. Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset.
Chan JF; Yao Y; Yeung ML; Deng W; Bao L; Jia L; Li F; Xiao C; Gao H; Yu P; Cai JP; Chu H; Zhou J; Chen H; Qin C; Yuen KY
J Infect Dis; 2015 Dec; 212(12):1904-13. PubMed ID: 26198719
[TBL] [Abstract][Full Text] [Related]
6. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
Sheahan TP; Sims AC; Leist SR; Schäfer A; Won J; Brown AJ; Montgomery SA; Hogg A; Babusis D; Clarke MO; Spahn JE; Bauer L; Sellers S; Porter D; Feng JY; Cihlar T; Jordan R; Denison MR; Baric RS
Nat Commun; 2020 Jan; 11(1):222. PubMed ID: 31924756
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial.
Arabi YM; Asiri AY; Assiri AM; Aziz Jokhdar HA; Alothman A; Balkhy HH; AlJohani S; Al Harbi S; Kojan S; Al Jeraisy M; Deeb AM; Memish ZA; Ghazal S; Al Faraj S; Al-Hameed F; AlSaedi A; Mandourah Y; Al Mekhlafi GA; Sherbeeni NM; Elzein FE; Almotairi A; Al Bshabshe A; Kharaba A; Jose J; Al Harthy A; Al Sulaiman M; Mady A; Fowler RA; Hayden FG; Al-Dawood A; Abdelzaher M; Bajhmom W; Hussein MA;
Trials; 2020 Jan; 21(1):8. PubMed ID: 31900204
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome.
Kim UJ; Won EJ; Kee SJ; Jung SI; Jang HC
Antivir Ther; 2016; 21(5):455-9. PubMed ID: 26492219
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.
Momattin H; Mohammed K; Zumla A; Memish ZA; Al-Tawfiq JA
Int J Infect Dis; 2013 Oct; 17(10):e792-8. PubMed ID: 23993766
[TBL] [Abstract][Full Text] [Related]
10. Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Al-Tawfiq JA; Memish ZA
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):269-275. PubMed ID: 27937060
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
Wu L; Zheng Y; Liu J; Luo R; Wu D; Xu P; Wu D; Li X
Aging (Albany NY); 2021 Apr; 13(8):10833-10852. PubMed ID: 33879634
[TBL] [Abstract][Full Text] [Related]
14. [Potential antiviral therapeutics for 2019 Novel Coronavirus].
Li H; Wang YM; Xu JY; Cao B
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Mar; 43(3):170-172. PubMed ID: 32164080
[TBL] [Abstract][Full Text] [Related]
15. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
[TBL] [Abstract][Full Text] [Related]
16. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
[TBL] [Abstract][Full Text] [Related]
17. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen.
Spanakis N; Tsiodras S; Haagmans BL; Raj VS; Pontikis K; Koutsoukou A; Koulouris NG; Osterhaus AD; Koopmans MP; Tsakris A
Int J Antimicrob Agents; 2014 Dec; 44(6):528-32. PubMed ID: 25288266
[TBL] [Abstract][Full Text] [Related]
18. A review of treatment modalities for Middle East Respiratory Syndrome.
Mo Y; Fisher D
J Antimicrob Chemother; 2016 Dec; 71(12):3340-3350. PubMed ID: 27585965
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
Zhong H; Wang Y; Zhang ZL; Liu YX; Le KJ; Cui M; Yu YT; Gu ZC; Gao Y; Lin HW
Pharmacol Res; 2020 Jul; 157():104872. PubMed ID: 32360583
[TBL] [Abstract][Full Text] [Related]
20. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
